Université de Montréal

About: Université de Montréal is a education organization based out in Montreal, Quebec, Canada. It is known for research contribution in the topics: Population & Poison control. The organization has 45641 authors who have published 100476 publications receiving 4004007 citations. The organization is also known as: University of Montreal & UdeM.

Purification of Noisy Entanglement and Faithful Teleportation via Noisy Channels

Abstract: Two separated observers, by applying local operations to a supply of not-too-impure entangled states (e.g., singlets shared through a noisy channel), can prepare a smaller number of entangled pairs of arbitrarily high purity (e.g., near-perfect singlets). These can then be used to faithfully teleport unknown quantum states from one observer to the other, thereby achieving faithful transmission of quantum information through a noisy channel. We give upper and lower bounds on the yield $D\left(M\right)$ of pure singlets $(|{\ensuremath{\Psi}}^{\ensuremath{-}}〉)$ distillable from mixed states $M$, showing $D\left(M\right)g0$ if $〈{\ensuremath{\Psi}}^{\ensuremath{-}}|M|{\ensuremath{\Psi}}^{\ensuremath{-}}〉g\frac{1}{2}$.

Ward's Hierarchical Agglomerative Clustering Method: Which Algorithms Implement Ward's Criterion?

Abstract: The Ward error sum of squares hierarchical clustering method has been very widely used since its first description by Ward in a 1963 publication. It has also been generalized in various ways. Two algorithms are found in the literature and software, both announcing that they implement the Ward clustering method. When applied to the same distance matrix, they produce different results. One algorithm preserves Ward's criterion, the other does not. Our survey work and case studies will be useful for all those involved in developing software for data analysis using Ward's hierarchical clustering method.

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Abstract: A b s t r ac t Background Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. Methods In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival. Results The study was unblinded after a planned interim analysis that was performed after 43% of the expected deaths had occurred. The median radiographic progressionfree survival was 16.5 months with abiraterone–prednisone and 8.3 months with prednisone alone (hazard ratio for abiraterone–prednisone vs. prednisone alone, 0.53; 95% confidence interval [CI], 0.45 to 0.62; P<0.001). Over a median follow-up period of 22.2 months, overall survival was improved with abiraterone–prednisone (median not reached, vs. 27.2 months for prednisone alone; hazard ratio, 0.75; 95% CI, 0.61 to 0.93; P = 0.01) but did not cross the efficacy boundary. Abiraterone–predni sone showed superiority over prednisone alone with respect to time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, prostate-specific antigen progression, and decline in performance status. Grade 3 or 4 mineralocorticoid-related adverse events and abnormalities on liver-function testing were more common with abiraterone–prednisone. Conclusions Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer. (Funded by Janssen Research and Development, formerly Cougar Biotechnology; ClinicalTrials.gov number, NCT00887198.)

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals

Abstract: ContextMicroalbuminuria is a risk factor for cardiovascular (CV) events. The relationship between the degree of albuminuria and CV risk is unclear.ObjectivesTo estimate the risk of CV events in high-risk individuals with diabetes mellitus (DM) and without DM who have microalbuminuria and to determine whether levels of albuminuria below the microalbuminuria threshold increase CV risk.DesignThe Heart Outcomes Prevention Evaluation study, a cohort study conducted between 1994 and 1999 with a median 4.5 years of follow-up.SettingCommunity and academic practices in North and South America and Europe.ParticipantsIndividuals aged 55 years or more with a history of CV disease (n = 5545) or DM and at least 1 CV risk factor (n = 3498) and a baseline urine albumin/creatinine ratio (ACR) measurement.Main Outcome MeasuresCardiovascular events (myocardial infarction, stroke, or CV death); all-cause death; and hospitalization for congestive heart failure.ResultsMicroalbuminuria was detected in 1140 (32.6%) of those with DM and 823 (14.8%) of those without DM at baseline. Microalbuminuria increased the adjusted relative risk (RR) of major CV events (RR, 1.83; 95% confidence interval [CI], 1.64-2.05), all-cause death (RR, 2.09; 95% CI, 1.84-2.38), and hospitalization for congestive heart failure (RR, 3.23; 95% CI, 2.54-4.10). Similar RRs were seen for participants with or without DM, even after adjusting for other CV risk factors (eg, the adjusted RR of the primary aggregate end point was 1.97 [95% CI, 1.68-2.31] in those with DM and 1.61 [95% CI, 1.36-1.90] in those without DM).Compared with the lowest quartile of ACR (<0.22 mg/mmol), the RRs of the primary aggregate end point in the second quartile (ie, ACR range, 0.22-0.57 mg/mmol) was 1.11 (95% CI, 0.95-1.30); third quartile, 1.38 (95% CI, 1.19-1.60; ACR range, 0.58-1.62 mg/mmol); and fourth quartile, 1.97 (95% CI, 1.73-2.25; ACR range, >1.62 mg/mmol) (P for trend <.001, even after excluding those with microalbuminuria). For every 0.4-mg/mmol increase in ACR level, the adjusted hazard of major CV events increased by 5.9% (95% CI, 4.9%-7.0%).ConclusionsOur results indicate that any degree of albuminuria is a risk factor for CV events in individuals with or without DM; the risk increases with the ACR, starting well below the microalbuminuria cutoff. Screening for albuminuria identifies people at high risk for CV events.

Word Representations: A Simple and General Method for Semi-Supervised Learning

Abstract: If we take an existing supervised NLP system, a simple and general way to improve accuracy is to use unsupervised word representations as extra word features. We evaluate Brown clusters, Collobert and Weston (2008) embeddings, and HLBL (Mnih & Hinton, 2009) embeddings of words on both NER and chunking. We use near state-of-the-art supervised baselines, and find that each of the three word representations improves the accuracy of these baselines. We find further improvements by combining different word representations. You can download our word features, for off-the-shelf use in existing NLP systems, as well as our code, here: http://metaoptimize.com/projects/wordreprs/